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Background. BCV is a lipid conjugated nucleotide analog that has shown rapid viral clearance with oral administration in patients with adenovirus infection, and improved survival in animal models of smallpox. Phase I single ascending dose evaluation of IV BCV demonstrated that 2 hour infusions of 10, 25, and 50 mg were well tolerated and not associated with significant adverse events (AEs) or laboratory abnormalities. This study evaluated the safety and PK of multiple ascending doses of IV BCV in healthy subjects.
Methods. Twenty-eight subjects were to be randomized 3:1 to receive blinded IV BCV or placebo in sequential MAD cohorts (Table A) . Study drug was given twice a week (BIW) for 2 weeks or once a week (QW) for 4 weeks. Plasma PK samples were collected on Day 1 and after the last dose and assayed by HPLC-MS. Plasma BCV PK parameters were determined by noncompartmental analysis and dose proportionality and accumulation was assessed. Safety assessments were performed during the dosing period through 14 days post last dose.
Results. Twenty-seven male and female subjects (29-65 years, 93% White) were enrolled and 26 completed the study. Plasma BCV C max and AUC ∞ increased in proportion to dose with no accumulation (Table A) . AEs were generally mild and included diarrhea and headache. Alanine aminotransferase (ALT) elevations were asymptomatic and resolved upon cessation of dosing. No serious AEs occurred. Conclusion. Multiple doses of IV BCV given as 10 mg BIW or 20 mg QW were generally safe and well tolerated. Mild diarrhea was reported only after IV BCV 20 mg QW. As seen with oral BCV, ALT increases were reversible upon cessation of drug, and were not associated with hyperbilirubinemia. BCV exposure was dose-proportional Conclusion. Both ATM-AVI and CAZ-AVI displayed very high TA% (>95%) for CR-EC, CR-KP, and CR-ENT at both PD targets. However, TA% for MBL-ENT was very low for CAZ-AVI and ≥99% for ATM-AVI. Against CR-PA, CAZ-AVI was had much higher TA% than ATM-AVI (87-93% vs. 43-48%). These differences suggest different roles for each drug combination in clinical practice.
Disclosures. All authors: No reported disclosures. Background. Pneumonia is a major cause of mortality in critically ill patients. Sitafloxacin, broad-spectrum fluoroquuinolone, has an in vitro activity against many drug-resistant pathogens causing pneumonia. The objectives of this study were to determine epithelial lining fluid (ELF) concentrations of sitafloxacin and compare those with plasma, including pharmacokinetic (PK) parameters in Thai critically ill patients.
Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai
Methods. Sitafloxacin concentrations were determined using LC-MS/MS assay. Twelve critically ill patients with pneumonia were enrolled to receive oral sitafloxacin 200 mg single dose. Serial blood samples were collected in each patient (seven time points) prior to dose and over 12-hour interval. BAL samples were collected once in each patient simultaneously with plasma sampling. Intrapulmonary penetration was evaluated as the ELF to unbound plasma concentration ratio calculated by fraction unbound related to albumin concentration in each patient. A compartment model was applied to describe plasma PK parameters using WinNonLin software.
Results. The median age was 57 years with median weight was 52 kg. The highest penetration ratio of ELF to unbound plasma concentrations based on median value was 1.3, observed during 5-6 hours ( Table 1 ). The data fitted to one-compartment model that described absorption, distribution and elimination. PK parameters are presented in Table 2 .
Conclusion. Oral sitafloxacin well penetrate into ELF at a penetration ratio of 130% related to unbound plasma in Thai critically ill patients. Sitafloxacin is a promising agent for treatment of lower respiratory tract infections caused by susceptible pathogens in intensive care unit. 
